Merck & Co. (NYSE: MRK) is the Rahway, New Jersey pharmaceutical company behind Keytruda, the cancer drug with the highest sales in its portfolio. Merck reported full-year 2025 worldwide sales of $65.0 billion, of which Keytruda and its subcutaneous version Keytruda Qlex made up $31.7 billion, according to Merck's February 3, 2026 results release. Robert M. Davis is chairman and chief executive officer, and the company operates as MSD outside the United States and Canada.
Part of EPR's Pharma pillar and Healthcare pillar. This is the Merck & Co. coverage hub on Everything-PR. By the EPR Editorial Team, updated October 2026. This page describes a company and its communications, and it is not medical advice.
What are the key facts about Merck & Co.?
| Fact | Detail |
| Founded | 1891, as the U.S. arm of the German company E. Merck |
| Headquarters | Rahway, New Jersey |
| Ticker | NYSE: MRK |
| Chairman and CEO | Robert M. Davis, CEO since July 2021 |
| 2025 worldwide sales | $65.0 billion (1% growth), per Merck |
| 2025 Keytruda and Keytruda Qlex sales | $31.7 billion (7% growth), per Merck |
| 2025 Animal Health sales | $6.4 billion (8% growth), per Merck |
Merck & Co. and the German company Merck KGaA are two separate companies. Merck & Co. began as the U.S. subsidiary of E. Merck and became independent after World War I, when U.S. assets of German-owned companies were seized and sold.
What is Keytruda, and why does it matter to Merck?
Keytruda (pembrolizumab) is a PD-1 immune checkpoint inhibitor first approved by the FDA in September 2014 for advanced melanoma. Merck's filings say it is now approved in the U.S. in over 45 indications across 19 tumor types and two tumor-agnostic indications. It made up roughly half of Merck's 2025 sales, which is why the company's strategy centers on what comes after it.
Keytruda Qlex, a subcutaneous version of Keytruda combined with berahyaluronidase alfa, was first approved by the FDA in September 2025 for solid tumor indications approved for Keytruda, and the European Commission approved a subcutaneous version in November 2025. Merck also discloses litigation with Halozyme about the technology.
What is the Keytruda patent cliff?
The Keytruda patent cliff is the expected loss of U.S. market exclusivity for the drug in 2028, as widely reported, after which biosimilar competition is expected to reduce its revenue. Merck's response has three parts: subcutaneous formulations, expanded indications, and acquisitions. EPR describes the cliff as the largest single revenue-replacement challenge in the industry, which is EPR's characterization.
How is Merck replacing Keytruda revenue?
Merck is buying and licensing new products. The table lists the deals EPR has verified against Merck's disclosures.
| Deal | Date | What it added |
| Acceleron Pharma | November 2021 | Sotatercept, approved as Winrevair for pulmonary arterial hypertension in March 2024 |
| Prometheus Biosciences | June 2023 | A TL1A-targeting drug for inflammatory bowel disease |
| Daiichi Sankyo collaboration | October 2023 | Three antibody-drug conjugates in oncology |
| Verona Pharma | Closed October 2025 | Ohtuvayre, a maintenance treatment for COPD, in an acquisition of about $10 billion |
| Cidara Therapeutics | Closed January 2026 | A long-acting antiviral designed to prevent influenza |
Winrevair sales were $1.4 billion in 2025, per Merck's results release.
What other products does Merck sell?
Merck's other major products include the HPV vaccine Gardasil and Gardasil 9, which had $5.2 billion in 2025 sales, a 39% decline, per Merck. It also sells Bridion for reversing neuromuscular blockade during surgery, Welireg for certain kidney cancers, and Lagevrio, an oral COVID-19 antiviral that received an FDA emergency use authorization in December 2021. Merck Animal Health sells veterinary medicines and vaccines, including Bravecto and Nobivac. Merck spun off its women's health and biosimilars business as Organon in June 2021.
How does Merck handle communications?
Merck's communications work centers on three recurring tasks. It supports Keytruda across dozens of cancer indications through trade press and scientific affairs. It explains the post-Keytruda strategy to investors. And it manages pricing policy, including the Inflation Reduction Act, under which Januvia was among the first drugs selected for Medicare price negotiation. EPR's observation is that CEO Davis has a lower public profile than some peers, and that Merck leans on scientific affairs and trade press over consumer-facing CEO visibility.
How does Merck rank in AI answers?
In EPR's Pharma AI Citation Share Study, Merck ranks fifth among large pharma companies despite owning a top-selling drug, and EPR concludes that advertising spend does not predict AI citation share. These are EPR's own study results. See also Pharma Spent $8 Billion on TV. The Chatbox Cited Eli Lilly Anyway.